The Unite-CNM trial (NCT04033159) aimed to assess the effect of an antisense oligonucleotide to reduce <i>DNM2</i> mRNA expression in X-linked myotubular myopathy (XLMTM) and autosomal dominant centronuclear myopathy (ADCNM).<h4>Objective</h4>The trial was discontinued due to tolerability concerns (hepatic and hematological). Here, DNM2 is linked to X-linked myotubular myopathy.